Modulators of diacyglycerol acyltransferase 2 (DGAT2)
AssigneeIonis Pharmaceuticals, Inc.
InventorEric E. Swayze
Life of this patent
Estimating the term…
Abstract
The present embodiments provide methods, compounds, and compositions useful for inhibiting DGAT2 expression, which may be useful for treating, preventing, or ameliorating a disease associated with DGAT2.
Claims13
A method of treating, preventing, or ameliorating NAFLD, NASH, lipodystrophy, or partial lipodystrophy in an individual comprising administering to the individual a compound comprising or consisting of a modified oligonucleotide according to the following formula:
- or a salt thereof;
- wherein administering the compound reduces or inhibits triglyceride synthesis, lipid synthesis and/or insulin resistance in the liver or white adipose tissue of the individual;
- thereby treating, preventing, or ameliorating NAFLD, NASH, lipodystrophy, or partial lipodystrophy.
A method of treating, preventing, or ameliorating NAFLD, NASH, lipodystrophy, or partial lipodystrophy in an individual comprising administering to the individual a compound comprising or consisting of a modified oligonucleotide according to the following formula:
- wherein administering the compound reduces or inhibits triglyceride synthesis, lipid synthesis, and/or insulin resistance, or improves insulin signaling, insulin sensitivity and/or cardiovascular risk profile in the individual;
- thereby treating, preventing, or ameliorating NAFLD, NASH, lipodystrophy, or partial lipodystrophy.
Dependencies are inferred from the claim text.